Myasthenia gravis (MG) has been treatable for nearly 100 years. In 1934, the Scottish doctor Mary Broadfoot Walker, MD, discovered that the drug physostigmine improved muscle function in people with ...

The treatment landscape of generalised myasthenia gravis, a prototypic antibody-mediated disorder of the neuromuscular junction, has considerably evolved in the past 8 years.1 The approval of targeted ...

It’s a lifelong autoimmune neuromuscular disease. It causes certain muscles to weaken easily after you use them. Muscle fatigue typically varies throughout the day (sometimes hour by hour) and gets ...

Myasthenia gravis usually does not shorten life expectancy, but severe muscle weakness that affects breathing can be life threatening. Myasthenia gravis symptoms may begin suddenly and often progress ...

Myasthenia gravis (MG) is a chronic autoimmune neuromuscular condition that causes muscle weakness and severe fatigue. The fatigue associated with MG is often described as fatigable weakness, meaning ...

Myasthenia gravis patients show higher rates of dysarthria, dysphonia, dysphagia, and aspiration pneumonia compared to non-affected individuals. Despite high disorder rates, most myasthenia gravis ...

Doctors may recommend oral medications such as pyridostigmine and various intravenous (IV) drugs for the treatment of myasthenia gravis. Thymectomy surgery and plasma exchange may also help. The aim ...